)
Aclaris Therapeutics (ACRS) investor relations material
Aclaris Therapeutics Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Pipeline updates and priorities
Bosakitug, a TSLP monoclonal antibody, missed the atopic dermatitis endpoint; the small study showed robust Th1, Th17 and Th2 pharmacodynamic responses, while single-agent TSLP was not part of the base plan.
Modzatinib 2138’s oral lichen planus study started last week and will cover mucosal, cutaneous and scalp phenotypes.
The 9494 next-generation ITK program completed required toxicology; filing is planned in the coming weeks, followed by SAD/MAD studies and proof of concept in 2027.
9494 is being developed for TH2-based oral indications, potentially atopic disease or asthma; disease-related measures such as elevated FeNO may be included in MAD work.
A second indication for the 052 bispecific, either asthma or atopic dermatitis, is expected to be selected before year-end; designs may include a positive control or Dupixent failures.
052 bispecific and EoE strategy
EoE is now the lead indication for 052; tezepelumab’s positive data increased the rationale for a larger study focused initially on EoE.
KOLs cited rising EoE prevalence, potentially exceeding 1 million patients, and TSLP’s potential to address broader inflammatory pathways beyond eosinophils.
The EoE study is expected in 2027, with histologic, symptom and endoscopic outcomes; the aim is an efficient design that moves rapidly from phase 2 toward registration.
Target profile includes faster onset and greater depth or breadth of response; management also anticipates evaluating induction and maintenance approaches and longer dosing intervals.
Oral lichen planus study
The 2138 basket study starts with oral disease, then plans cutaneous and scalp cohorts; target enrollment is 35–40 patients, with interim analysis after ~60% reach week 16.
ODSS is the primary endpoint; IGA and patient-reported outcomes are also included. ODSS is a continuous 0–106 measure and was used to power the initial cohort.
After interim results, the plan is to consult the FDA on the registrational program; Fast Track designation enables further agency interaction.
Management cited ITK’s upstream mechanistic fit with T-cell receptor-driven disease and viewed an ODSS response near 50% as compelling.
A recent topical corticosteroid study in milder oral disease showed a 20% response rate; management noted the different disease severity and lower baseline ODSS scores.
- Positive ATI-052 data and October financing support an expected cash runway through H1 2029.ACRS
Q3 2026 - ATI-052 showed AD and asthma activity; next-stage development will prioritize EoE.ACRS
Study result - Multiple late-stage readouts and new trials in I&I set the stage for significant pipeline progress.ACRS
12th Annual Cantor Fitzgerald Global Healthcare Conference - Net loss rose to $41.3M as R&D spending increased, with $170.6M liquidity and major clinical milestones ahead.ACRS
Q2 2026 - Advancing TSLP biologics and ITK/JAK3 inhibitors with late 2026 clinical catalysts expected.ACRS
Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - Key bispecific and TSLP mAb data readouts expected in H2, with phase II asthma trial starting Q4.ACRS
Jefferies Global Healthcare Conference 2026 - All proposals passed, with board elections, compensation, and auditor ratification approved.ACRS
AGM 2026 - Multiple late-stage immunology assets advance toward key 2024 and 2026 milestones, backed by strong funding.ACRS
Bank of America Global Healthcare Conference 2026 - Lead assets show strong efficacy and safety in large immune disease markets, with cash runway to 2028.ACRS
Corporate presentation
Next Aclaris Therapeutics earnings date
Next Aclaris Therapeutics earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)